Want to see HNGE full AI Analyst Report?
HNGE Stock Chart & Stats
$87.35
$1.40(1.88%)
At close: 4:00 PM EDT
$87.35
$1.40(1.88%)
Day’s Range― - ―
52-Week Range$30.08 - $96.66
Previous Close$36.79
Volume368.85K
Average Volume (3M)1.83M
Market Cap
$7.66B
Enterprise Value$6.54K
Total Cash (Recent Filing)$389.39M
Total Debt (Recent Filing)$5.88M
Price to Earnings (P/E)70.1
Beta1.74
Next Earnings
Nov 03, 2026EPS Estimate
0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.35
Shares Outstanding62,468,720
10 Day Avg. Volume2,019,052
30 Day Avg. Volume1,830,720
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)9.72
Price to Sales (P/S)6.26
P/FCF Ratio21.54
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$106.08Price Target Upside21.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)2.35
Revenue Forecast (FY)$856.78M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue And Billings GrowthRapid revenue and billings growth indicates strong employer and health-plan adoption, while billings provide forward visibility. Continued client wins and expanding eligible lives can support durable scale over the next several quarters.
Improving Margins And Cash GenerationHigher operating leverage, care-team efficiency, and automation are improving profitability as the business scales. Strong free cash flow also funds product investment, acquisitions, and shareholder returns without relying heavily on debt.
Platform Expansion And Clinical DifferentiationExpansion beyond MSK increases the addressable market and strengthens Hinge’s multi-condition platform. Clinical evidence can reinforce buyer ROI claims, improve credibility with health plans, and support broader adoption over time.
Bears Say
Severe Accounting Profitability VolatilityThe sharp gap between strong growth and a very large accounting loss raises questions about cost scalability, one-time charges, and earnings quality. Until profitability proves repeatable, reported results may remain volatile.
Cylinder Integration And Maturity RiskIntegrating products, technology, and operations may divert management attention and temporarily pressure margins. Cylinder’s smaller, less mature profile also creates execution risk before the acquisition can deliver its expected longer-term growth.
Reliance On Yield Improvements Amid CompetitionFuture outperformance depends on sustaining engagement, referrals, renewals, and revenue per eligible life rather than pricing or membership expansion alone. Intensifying competition could make those yield gains and customer wins harder to maintain.
Hinge Health, Inc. Class A News
HNGE FAQ
What was Hinge Health, Inc. Class A’s price range in the past 12 months?
Hinge Health, Inc. Class A lowest stock price was $30.08 and its highest was $96.66 in the past 12 months.
What is Hinge Health, Inc. Class A’s market cap?
Hinge Health, Inc. Class A’s market cap is $7.66B.
When is Hinge Health, Inc. Class A’s upcoming earnings report date?
Hinge Health, Inc. Class A’s upcoming earnings report date is Nov 03, 2026 which is in 42 days.
How were Hinge Health, Inc. Class A’s earnings last quarter?
Hinge Health, Inc. Class A released its earnings results on Aug 04, 2026. The company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.615 by -$0.025.
Is Hinge Health, Inc. Class A overvalued?
According to Wall Street analysts Hinge Health, Inc. Class A’s price is currently Undervalued.
Does Hinge Health, Inc. Class A pay dividends?
Hinge Health, Inc. Class A does not currently pay dividends.
What is Hinge Health, Inc. Class A’s EPS estimate?
Hinge Health, Inc. Class A’s EPS estimate is 0.6.
How many shares outstanding does Hinge Health, Inc. Class A have?
Hinge Health, Inc. Class A has 62,468,720 shares outstanding.
What happened to Hinge Health, Inc. Class A’s price movement after its last earnings report?
Hinge Health, Inc. Class A reported an EPS of $0.59 in its last earnings report, missing expectations of $0.615. Following the earnings report the stock price went up 1.725%.
Which hedge fund is a major shareholder of Hinge Health, Inc. Class A?
Currently, no hedge funds are holding shares in HNGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hinge Health, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$106.08 (21.45% Upside)
$106.08 (21.45% Upside)
Blogger Sentiment
Bullish
HNGE Sentiment 63%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 293.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $213.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 14.3%
Last 30 Days ▲ 14.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Hinge Health, Inc. Class A
Established in 2012 and headquartered in San Francisco, California, Hinge Health, Inc. creates specialized healthcare software solutions for musculoskeletal and joint health. Their advanced platform is designed to comprehensively manage a spectrum of needs, including general musculoskeletal care, acute injuries, persistent chronic pain, and post-operative rehabilitation. Furthermore, the company provides essential administrative and operational assistance.
HNGE Company Deck
HNGE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive operational and financial story: high top-line growth (+53% Q2 revenue), substantial billings momentum (+52% LTM billings), marked margin and free cash flow expansion (operating margin +1,000 bps YoY; free cash flow 3x YoY), raised guidance, and concrete product/TAM expansion (Migraine traction and the $105M Cylinder acquisition to enter GI). Key risks are manageable near-term execution items — integrating Cylinder, some non-recurring margin tailwinds (tariff refund), reliance on continued yield improvements for upside, and heightened competitive noise. Overall, the positives (growth, profitability, cash generation, product traction, and clinical evidence) materially outweigh the near-term integration and concentration risks.View all HNGE earnings summariesHNGE Stock 12 Month Forecast
Average Price Target
$106.08
▲(21.45% Upside)
Technical Analysis
Ownership Overview
7.23% Insiders
17.08% Mutual Funds
36.92% Other Institutional Investors
26.33% Public Companies and
Individual Investors